CompletedNot Applicable

Post-marketing Surveillance of Linaclotide Tablet in Patients With Irritable Bowel Syndrome With Constipation or Chronic Constipation (Excluding Constipation Due to Organic Diseases)

Japan2,475 participantsStarted 2017-10-02

Plain-language summary

The objective of this study is to evaluate the long-term safety and efficacy of linaclotide in post-marketing use.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with Irritable Bowel Syndrome with Constipation (IBS-C) or Chronic Constipation (CC) (excluding constipation due to organic diseases) who have used linaclotide for the first time

What they're measuring

Incidence of diarrhea

Timeframe: Up to Week 36

Trial details

NCT IDNCT03471728

SponsorAstellas Pharma Inc

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2021-12-31

View on ClinicalTrials.gov More Chronic Constipation (CC) (Excluding Constipation Due to Organic Diseases) trials